Case Control Study

Interleukin-21 gene polymorphisms and chronic hepatitis B infection in a Chinese population

Jia-Yan Yao, Kang Chao, Min-Rui Li, Yan-Qing Wu, Bi-Hui Zhong

Jia-Yan Yao, Kang Chao, Min-Rui Li, Yan-Qing Wu, Bi-Hui Zhong, Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China

Author contributions: Yao JY wrote the manuscript and performed the data analysis; Yao JY, Li MR and Wu YQ performed the majority of experiments; Chao K and Yao JY designed the research; Zhong BH revised the paper.

Supported by National Natural Science Foundation of China, No. 81170392.

Ethics approval: The study was reviewed and approved by the First Affiliated Hospital of Sun Yat-Sen University Institutional Review Board.

Informed consent: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Data sharing: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Bi-Hui Zhong, MD, PhD, Division of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University, No. 58 Zhongshan Road II, Guangzhou 510080, Guangdong Province, China. sophiazhong@medmail.com.cn

Telephone: +86-20-87755766
Fax: +86-20-87332916
Received: October 30, 2014
Peer-review started: October 31, 2014
First decision: November 26, 2014
Revised: December 19, 2014
Accepted: February 16, 2015
Article in press: February 16, 2015
Published online: April 14, 2015

Abstract

AIM: To investigate the relationship between interleukin-21 (IL21) gene polymorphisms and chronic hepatitis B virus (HBV) infection in a Chinese population.

METHODS: In this case-control study, 366 Chinese HBV-infected patients were recruited and divided into hepatocellular carcinoma (HCC; n = 94) and non-HCC (n = 272) groups at The First Affiliated Hospital of Sun Yat-Sen University, from April 2009 to December 2012. In the non-HCC group, the patients were classified into three clinical subsets, 76 patients had chronic hepatitis B, 101 were HBV carriers and 95 patients had HBV-related cirrhosis. Two hundred eight unrelated healthy controls were also included. Genomic DNA was extracted from peripheral blood. Single nucleotide polymorphisms (SNPs) rs13143866, rs2221903, and rs907715 were subsequently genotyped using the SNaPshot SNP technique.

RESULTS: There were no significant differences in allele and genotype frequencies of SNPs rs13143866, rs2221903, and rs907715 between chronic HBV-infected patients and control subjects. Furthermore, no significant differences were found in the frequencies of all alleles and genotypes between the HCC group and the non-HCC group. However, in the subgroup analysis, IL21 rs13143866 genotype AA frequency in the HBV carrier group was higher than in controls (OR = 6.280, 95%CI: 1.238-31.854; P = 0.019), and the effect of the recessive model (AA vs GG + GA, OR = 6.505, 95%CI: 1.289-32.828) was observed in the HBV carrier group. IL21 rs2221903 genotype TC frequency in the HBV carrier group was higher than in controls (OR = 1.809, 95%CI: 1.043-3.139; P = 0.035). In the haplotype analysis, the ATA haplotype (rs13143866, rs2221903, and rs907715) of IL21 was more frequent in the HCC group than in the non-HCC group (0.165 vs 0.104, P = 0.044; OR = 1.700, 95%CI: 1.010-2.863).

CONCLUSION: Genotypes rs13143866 AA and rs2221903 TC are risk factors for carrying HBV; ATA haplotype increases the risk of HBV-related HCC onset.
in a Chinese population.

**Key words:** Chinese population; Chronic hepatitis B virus infection; Interleukin-21 gene; rs13143866; rs2221903; rs907715; Single-nucleotide polymorphism

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This study is the first to investigate the relationship between single nucleotide polymorphism rs13143866 of the interleukin-21 gene and chronic hepatitis B virus (HBV) infection in a Chinese population. We found that genotypes rs13143866 AA and rs2221903 TC were risk factors for carrying HBV, and the ATA haplotype (rs13143866, rs2221903 and rs907715) increased the risk of HBV-related hepatocellular carcinoma.

Yao JY, Chao K, Li MR, Wu YQ, Zhong BH. Interleukin-21 gene polymorphisms and chronic hepatitis B infection in a Chinese population. *World J Gastroenterol* 2015; 21(14): 4232-4239. Available from: URL: http://www.wjgnet.com/1007-9327/full/v21/i14/4232.htm DOI: http://dx.doi.org/10.3748/wjg.v21.i14.4232

**INTRODUCTION**

Approximately one-third of the world’s population has serologic evidence of past or present infection with hepatitis B virus (HBV), and 350-400 million people are chronic HBV surface antigen (HBsAg) carriers. The spectrum of disease and natural history of chronic HBV infection are diverse and variable, ranging from an inactive carrier state to progressive chronic hepatitis B (CHB), which may evolve to cirrhosis and hepatocellular carcinoma (HCC)[1]. An epidemiologic serosurvey of hepatitis B in China showed that the weighted prevalence of HBsAg in the Chinese population aged 1-59 years was 7.2%[2], which indicated that there were approximately 93 million people infected with HBV in China[3].

Interleukin (IL)-21, mainly produced by a range of differentiated CD4+ T-cell subsets, is a relatively recently discovered multifunctional and pleiotropic cytokine[4,5]. It promotes proliferation and accumulation of Ag-specific CD8+ effector T-cells, and increases their survival and cytolytic potential[6]. It also has a significant influence on the regulation of B-cell functions. It promotes the differentiation of antigen-stimulated B cells into memory and antibody-secreting plasma cells, affects IgE production, and induces Ig switch to IgG1 and IgG3 production[7,8]. In addition, it induces the differentiation of naive T cells into Th17 cells, and is involved in the maturation, activation, and survival of natural killer cells[9-11]. Several in vivo studies in animal models have shown that IL-21 is essential for controlling chronic viral infections[12-14]. The adaptive immune response is greatly attenuated in chronic HBV infection. It is likely that the absence of CD4+ T-cells prevents the maturation of a functionally effective CD8+ T-cell response, and is the primary reason for viral persistence[15-18]. Recent investigations have shown that serum levels of IL-21 are increased in CHB patients and associated with severe liver inflammation[19]. The levels of IL-21 expression in the liver tissues are significantly associated with increased degrees of inflammation and fibrosis in CHB patients[20]. High serum IL-21 levels after 12 wk of antiviral therapy predict HBeAg seroconversion in CHB[21]. IL-21 enhances HBCAg-specific interferon-γ CD8+ T-cell proliferation, whereas treatment with anti-IL-21 inhibits expansion* in vitro[22]. Collectively, these findings suggest that IL-21 may play a critical role in HBV infection. However, the precise mechanisms underlying the effects of IL-21 on hepatitis B pathogenesis have not yet been elucidated. Genetic polymorphisms in *IL21* have been explored in genetic susceptibility to chronic HBV-infected diseases. One report finds that *IL21* rs2221903 TC is less frequent in the HBV patients than in the HBV infection resolvers or in controls[23]. In kidney transplant patients with acute rejection, frequencies of TT homoygote genotype and T allele of IL-21-G1472T (rs2055979) polymorphism and CC homoygote genotype and C allele of IL-21-C5250T (rs4833837) polymorphism are higher in the HBV-infected patients than in the HBV-noninfected patients[24]. Accordingly, this study was conducted to confirm the association of *IL21* rs13143866, rs2221903, and rs907715 gene polymorphisms with susceptibility to chronic HBV infection in a Chinese population.

**MATERIALS AND METHODS**

The study was performed in accordance with the Declaration of Helsinki of the World Medical Association and was approved by The First Affiliated Hospital of Sun Yat-Sen University Institutional Review Board. All patients signed an informed consent form for this investigation.

**Subjects**

According to the guideline for the prevention and treatment of CHB (2010 version) and the diagnostic criteria (modified during the 10th National Conference on Viral Hepatitis and Hepatopathy 2000, China), 366 independent chronic HBV-infected patients (103 female and 263 male; mean age 48.3 ± 11.8 years) were recruited from The First Affiliated Hospital of Sun Yat-Sen University from April 2009 to December 2012 and were divided into an HCC (n = 94) and non-HCC (n = 272) group. All patients with HCC were confirmed by pathology. The non-HCC group was classified into three clinical subsets, CHB (n = 76), HBV carrier (n =
Table 1  Demographic data for all groups

| Groups          | Sex (M/F) | P value1 | P value2 | Age (yr) | P value1 | P value2 |
|-----------------|-----------|----------|----------|----------|----------|----------|
| HBV infection   | 263/103   | 0.672    |          | 48.3 ± 11.8 | 0.657    |          |
| HCC             | 64/30     | 0.713    | 0.345    | 48.8 ± 12.2 | 0.935    | 0.589    |
| non-HCC         | 199/73    | 0.473    |          | 48.1 ± 11.7 | 0.345    |          |
| Carrier         | 71/24     | 0.416    |          | 47.9 ± 11.3 | 0.570    |          |
| CHB             | 58/18     | 0.310    |          | 46.5 ± 11.0 | 0.151    |          |
| Cirrhosis       | 70/31     | 1.000    |          | 49.4 ± 12.6 | 0.621    |          |
| Control         | 146/62    |          |          | 48.7 ± 11.3 |          |          |

1vs control group; 2between HCC and non-HCC groups; HBV: Hepatitis B virus; HCC: Chronic HBV-infected patients with hepatocellular carcinoma; non-HCC: Chronic HBV-infected patients without hepatocellular carcinoma; Carrier: HBV carriers; CHB: Patients with chronic hepatitis B; Cirrhosis: Patients with HBV-related cirrhosis.

Selection and genotyping of single-nucleotide polymorphisms

For selection of the single-nucleotide polymorphisms (SNPs), Haploview software (http://www.broad.mit.edu/mpg/haploview) was used to perform linkage disequilibrium and haplotype block analyses using HapMap phase genotype data for the chromosomal region 4:123,750,234..123,764,662 (CHB database, HapMap release 27). The amplicon of interest was a 14.4 kb region within IL21 and approximately 3 kb upstream and 3 kb downstream of the gene. Three previously reported SNPs (rs13143866, rs2221903, and rs907715) with minor allele frequency (MAF) ≥ 0.05 were chosen. Genomic DNA from peripheral blood was extracted using nucleoside analogues or interferon, before diagnosis. This study also included 208 geographically and ethnically matched unrelated healthy controls (62 female and 146 male; mean age 48.7 ± 11.3 years). Exclusion criteria included the presence of autoimmune diseases and other liver diseases, such as alcoholic liver disease, silt hemorrhagic liver disease, autoimmune liver disease, and intra-and extrahepatic bile duct stones.

Statistical analysis

Distributions of the allele and genotype frequencies were calculated by the χ² test or Fisher’s exact test. ORs and 95% CIs of genotype frequencies were adjusted by logistic regression analysis. All analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, United States). The Hardy-Weinberg equilibrium test and the haplotype analysis were completed by SHEsis software (http://analysis.bio-x.cn/myAnalysis.php). All two-sided P < 0.05 were considered statistically significant.

RESULTS

Demographic data on each group are shown in Table 1. The allele and genotype frequencies of the three SNPs in IL21 in the HBV-infected patients and control subjects are shown in Table 2. The Hardy-Weinberg equilibrium P value in each group was > 0.01.

Association between IL21 polymorphisms and HBV infection

Although there was no statistically significant difference, our data showed a tendency that SNP rs2221903 was associated with an increased risk of chronic HBV infection. The frequency of allele C was 13.7% in the chronic HBV infection group and 10.3% in the control group. Furthermore, the effect of the dominant model was observed (Table 2).
Haplotype analysis
The results showed that the ATA haplotype (rs13143866, rs2221903, and rs907715) was significantly associated with HBV-related HCC and appeared to be a risk haplotype ($P = 0.044$) (Table 5).

**Table 2** Comparison of interleukin-21 polymorphisms between chronic hepatitis B virus-infected patients and controls $n$ (%)

| Polymorphism | HBV infection ($n = 366$) | Control ($n = 208$) | $P$ value | OR (95% CI) |
|--------------|---------------------------|---------------------|-----------|-------------|
| rs13143866   |                           |                     |           |             |
| Allele frequency | Allele G            | 621 (85.5)          | 363 (87.3) | 0.259       | Reference   |
|               | Allele A             | 111 (14.5)          | 53 (12.7)  | 1.224       | 0.861-1.741 |
| Genotype frequency | GG                 | 266 (72.7)          | 157 (75.5) | Reference   |
|               | GA                  | 89 (24.3)           | 49 (23.5)  | 0.734       | 0.625-1.392 |
|               | AA                  | 11 (3.0)            | 2 (1.0)    | 0.290$^2$   | 0.067-1.408 |
|               | HW 258 (0.94)       | 0.591               |           |             |
| Recessive model | GG + GA             | 355 (97.0)          | 206 (99.0) | Reference   |
|               | AA                  | 11 (3.0)            | 2 (1.0)    | 0.149$^2$   | 3.195 (0.703-14.493)   |
| Dominant model | GG                 | 266 (72.7)          | 157 (75.5) | Reference   |
|               | AA + GA             | 100 (27.3)          | 51 (24.5)  | 0.463       | 1.157 (0.783-1.711)   |
| rs2221903    |                           |                     |           |             |
| Allele frequency | Allele T            | 632 (86.3)          | 373 (89.7) | 0.101       | 1.373 (0.939-2.006)   |
|               | Allele C            | 100 (13.7)          | 43 (10.3)  | Reference   |
| Genotype frequency | TT                  | 272 (74.3)          | 167 (80.3) | Reference   |
|               | TC                  | 88 (24.1)           | 39 (18.7)  | 0.130       | 1.285 (0.907-1.116)   |
|               | CC                  | 6 (1.6)             | 2 (1.0)    | 0.262$^2$   | 1.842 (0.367-9.232)   |
|               | HW 0.712            | 0.868               |           |             |
| Recessive model | TT + TC             | 360 (98.4)          | 206 (99.0) | Reference   |
|               | CC                  | 6 (1.6)             | 2 (1.0)    | 0.717$^2$   | 1.715 (0.342-8.547)   |
| Dominant model | TT                 | 272 (74.3)          | 167 (80.3) | Reference   |
|               | CC + TC             | 94 (25.7)           | 41 (19.7)  | 0.105       | 1.408 (0.930-2.130)   |
| rs907715     |                           |                     |           |             |
| Allele frequency | Allele G            | 415 (56.7)          | 234 (56.2) | 0.884       | 0.982 (0.770-1.252)   |
|               | Allele A            | 317 (43.3)          | 182 (43.8) | Reference   |
| Genotype frequency | GG                 | 110 (30.0)          | 70 (33.7)  | Reference   |
|               | GA                  | 195 (53.3)          | 94 (45.2)  | 0.160       | 1.320 (0.896-1.945)   |
|               | AA                  | 61 (16.7)           | 44 (21.1)  | 0.155       | 0.882 (0.540-1.440)   |
|               | HW 0.101            | 0.238               |           |             |
| Recessive model | GG + GA             | 305 (83.3)          | 164 (78.8) | Reference   |
|               | AA                  | 61 (16.7)           | 44 (21.2)  | 0.181       | 0.746 (0.484-1.148)   |
| Dominant model | GG                 | 110 (30.1)          | 70 (33.7)  | Reference   |
|               | AA + GA             | 256 (69.9)          | 138 (66.3) | 0.372       | 1.181 (0.820-1.699)   |

$^1$The $P$ values of rs13143866, rs2221903, and rs907715 genotype distribution between chronic HBV-infected patients and controls were 0.237, 0.876, 0.358, respectively; Fisher’s exact test. HWE: Hardy-Weinberg equilibrium.

**Association between IL21 polymorphisms and HCC**
No significant differences were found in the frequencies of all alleles and genotypes (rs13143866, rs2221903, and rs907715) between the HCC group and the non-HCC group (Table 3).

**Association between IL21 polymorphisms and HBV infection subgroups**
The distribution of genotypes and alleles of $IL21$ rs907715 polymorphisms showed no significant difference among HBV carriers, patients with CHB, patients with HBV-related cirrhosis, and healthy controls. However, $IL21$ rs13143866 and rs2221903 polymorphisms were differently distributed between the HBV carrier group and controls (Table 4). $IL21$ rs13143866 genotype AA frequency in the HBV carrier group was higher than in controls (5.9% vs 1.0%, $P = 0.019$), and the effect of the recessive model (AA vs GG + GA, $P = 0.017$) was observed in the HBV carrier group. $IL21$ rs2221903 genotype TC frequency in the HBV carrier group was higher than in controls (29.7% vs 18.7%, $P = 0.035$).

**DISCUSSION**
In this study, we analyzed allele and genotype frequencies at three SNPs of the $IL21$ gene in 366 chronic HBV-infected patients and 208 healthy controls in a Chinese population. The intronic SNPs may not be the actual risk mutation, but they are likely to be a surrogate marker for a mutation with functional consequences. The intronic SNPs may be in high linkage disequilibrium with a variant that associates with translation of the mRNA.$^{[25]}$ In other words, they may associate with protein expression. For example, synonymous SNPs have a substantial contribution to human disease risk and other complex traits.$^{[26]}$ Literature reports explored $IL21$ rs907715 and rs2221903 and $IL21R$ T-B3C and rs3093301.
Table 3 Interleukin-21 polymorphisms among chronic hepatitis B virus-infected patients with hepatocellular carcinoma, patients without hepatocellular carcinoma, and controls n (%)

| Polymorphism | HCC (n = 94) | non-HCC (n = 272) | Control (n = 208) | P value | OR (95%CI) | HCC vs non-HCC | P value | OR (95%CI) | HCC vs Control | P value | OR (95%CI) | non-HCC vs Control |
|--------------|-------------|-----------------|-----------------|---------|----------|---------------|---------|----------|---------------|---------|----------|------------------|
| rs13143866   |             |                 |                 |         |          |               |         |          |               |         |          |                  |
| Allele       |             |                 |                 |         |          |               |         |          |               |         |          |                  |
| Allele G     | 167 (88.8)  | 454 (83.5)      | 363 (87.3)      | 0.078   | 1.576 (0.949-2.617) | Reference | 0.586  | 0.861 (0.503-1.474) | Reference | 0.102  | 1.358 (0.941-1.958) | Reference |
| Allele A     | 21 (11.2)   | 90 (16.5)       | 53 (12.7)       | 0.231   | 1.420 (0.800-2.520) | Reference | 0.522  | 0.823 (0.453-1.495) | Reference | 0.470  | 1.168 (0.766-1.781) | Reference |
| Genotype     |             |                 |                 |         |          |               |         |          |               |         |          |                  |
| GG           | 74 (78.7)   | 192 (70.6)      | 157 (75.5)      | 0.248   | 3.854 (0.485-30.637) | Reference | 1.000  | 1.061 | Reference     |         |          |                  |
| GA           | 19 (20.2)   | 70 (25.7)       | 49 (23.5)       | 0.391   | 0.255 (0.122-0.539) | Reference | 0.074  | 4.089 (0.883-18.934) | Reference | 0.077  | 3.931 (0.852-18.139) | Reference |
| AA           | 1 (1.1)     | 10 (3.7)        | 2 (1.0)         |         |          |               |         |          | Reference     |         |          |                  |
| recessive    |             |                 |                 |         |          |               |         |          |               |         |          |                  |
| HWE          | 0.857       | 0.262           | 0.391           |         |          |               |         |          | Reference     |         |          |                  |
| recessive    |             |                 |                 |         |          |               |         |          | Reference     |         |          |                  |
| Dominant     |             |                 |                 |         |          |               |         |          | Reference     |         |          |                  |
| model        |             |                 |                 |         |          |               |         |          | Reference     |         |          |                  |
| Allele G     | 74 (78.7)   | 192 (70.6)      | 157 (75.5)      | 0.129   | 1.542 (0.882-2.695) | Reference | 0.539  | 0.832 (0.463-1.495) | Reference | 0.234  | 1.283 (0.852-1.932) | Reference |
| Allele A     | 20 (21.3)   | 80 (29.4)       | 51 (24.5)       | 0.230   | 0.282 (0.036-2.231) | Reference | 1.000  | 1.108 | Reference     |         |          |                  |
| Genotype     |             |                 |                 |         |          |               |         |          | Reference     |         |          |                  |
| recessive    |             |                 |                 |         |          |               |         |          | Reference     |         |          |                  |
| model        |             |                 |                 |         |          |               |         |          | Reference     |         |          |                  |
| Allele G     | 74 (78.7)   | 192 (70.6)      | 157 (75.5)      | 0.129   | 1.542 (0.882-2.695) | Reference | 0.539  | 0.832 (0.463-1.495) | Reference | 0.234  | 1.283 (0.852-1.932) | Reference |
| Allele A     | 20 (21.3)   | 80 (29.4)       | 51 (24.5)       | 0.230   | 0.282 (0.036-2.231) | Reference | 1.000  | 1.108 | Reference     |         |          |                  |
| recessive    |             |                 |                 |         |          |               |         |          | Reference     |         |          |                  |
| model        |             |                 |                 |         |          |               |         |          | Reference     |         |          |                  |
| Allele G     | 74 (78.7)   | 192 (70.6)      | 157 (75.5)      | 0.129   | 1.542 (0.882-2.695) | Reference | 0.539  | 0.832 (0.463-1.495) | Reference | 0.234  | 1.283 (0.852-1.932) | Reference |
| Allele A     | 20 (21.3)   | 80 (29.4)       | 51 (24.5)       | 0.230   | 0.282 (0.036-2.231) | Reference | 1.000  | 1.108 | Reference     |         |          |                  |
| recessive    |             |                 |                 |         |          |               |         |          | Reference     |         |          |                  |
| model        |             |                 |                 |         |          |               |         |          | Reference     |         |          |                  |
| Allele G     | 74 (78.7)   | 192 (70.6)      | 157 (75.5)      | 0.129   | 1.542 (0.882-2.695) | Reference | 0.539  | 0.832 (0.463-1.495) | Reference | 0.234  | 1.283 (0.852-1.932) | Reference |
| Allele A     | 20 (21.3)   | 80 (29.4)       | 51 (24.5)       | 0.230   | 0.282 (0.036-2.231) | Reference | 1.000  | 1.108 | Reference     |         |          |                  |
| recessive    |             |                 |                 |         |          |               |         |          | Reference     |         |          |                  |
| model        |             |                 |                 |         |          |               |         |          | Reference     |         |          |                  |

The values of P, OR, and 95%CI were calculated using Fisher's exact test. HWE: Hardy-Weinberg equilibrium.

The statistical difference in genotype frequencies in the recessive model (AA vs GG + GA) of SNP rs13143866 showed that the A allele, when present in homozygotes, was a risk factor for carrying HBV. Furthermore, IL21 rs13143866 genotype AA frequency in the HBV carrier group was higher than that in controls. In other studies, rs13143866 was associated with recurrent idiopathic spontaneous miscarriage[23], juvenile idiopathic arthritis[24], and lupus[25]. Thus, rs13143866 is likely a key genetic factor in both autoimmune diseases and chronic HBV-infected diseases.

Previous studies showed a significant association between rs2221903 and systemic lupus erythematosus (SLE) in the Chinese, European-American, and African-American populations[25,29,30]. Although there was no statistical difference, our data showed that this SNP is also associated with an increased risk of chronic HBV infection. The frequency of allele C was 13.7% in the chronic HBV infection group and 10.3% in the control group. In the subgroup analysis, the frequency of the TC genotype in the HBV carrier group was higher than that in controls. However, Li et al[24] found the opposite result, where the C frequency in HBV-infected patients was lower than in controls (8.1% vs 12.4%, P = 0.023, OR = 0.625, 95%CI: 0.415-0.941) and the TC genotype was less frequent in HBV-infected patients than in controls (16.2% vs 24.7%, P = 0.017, OR = 0.589, 95%CI: 0.381-0.911). Several potential explanations need to be considered. Firstly, the regulatory mechanisms of IL21 intronic SNPs are still not clear. Secondly, chronic HBV infection is a complex complication related to other genetic and environmental factors[26].

Our data found no significant association between
Table 4 Interleukin-21 polymorphisms among non-hepatocellular carcinoma subgroups and controls \( \alpha (%) \)

| Polymorphism | Carrier | CHB | Cirrhosis | Control | Carrier vs control | CHB vs control | Cirrhosis vs control |
|--------------|---------|-----|-----------|---------|-------------------|----------------|---------------------|
| rs13143866   |         |     |           |         |                   |                |                     |
| Allele frequency |       |     |           |         |                   |                |                     |
| Allele G     | 170 (84.2) | 128 (84.2) | 156 (82.1) | 363 (87.3) | 0.294              | Reference       | Reference            |
| Allele A     | 32 (15.8)  | 24 (15.8)  | 34 (17.9)  | 53 (12.7)  | 1.289              | 0.348           | 1.095               |
| Genotype frequency |       |     |           |         |                   |                |                     |
| GC           | 75 (74.3)  | 53 (69.7)  | 64 (67.4)  | 157 (75.5) | Reference          | Reference       | Reference            |
| GA           | 20 (19.8)  | 22 (28.9)  | 28 (29.5)  | 49 (23.5)  | 0.854              | 0.345           | 0.227               |
| AA           | 6 (5.9)    | 1 (1.3)    | 3 (3.1)    | 2 (1.0)    | 0.019              | 6.280           | 1.001               |
| HWE          | 0.01      | 0.44      | 0.977     | 0.391     | Reference          | Reference       | Reference            |
| Recreational model |       |     |           |         |                   |                |                     |
| GC + GA      | 95 (94.1)  | 75 (96.7)  | 92 (96.8)  | 206 (99.0) | Reference          | Reference       | Reference            |
| AA           | 6 (5.9)    | 1 (1.3)    | 3 (3.2)    | 2 (1.0)    | 0.011              | 6.505           | 1.001               |
| Dominant model |       |     |           |         |                   |                |                     |
| GC           | 75 (74.3)  | 53 (69.7)  | 64 (67.4)  | 157 (75.5) | Reference          | Reference       | Reference            |
| AA + GA      | 26 (25.7)  | 23 (30.3)  | 31 (32.6)  | 51 (24.5)  | 0.816              | Reference       | Reference            |
| rs2221903    |         |     |           |         |                   |                |                     |
| Allele frequency |       |     |           |         |                   |                |                     |
| Allele T     | 172 (85.1) | 130 (85.5) | 167 (87.9) | 373 (89.7) | 0.105              | Reference       | Reference            |
| Allele C     | 30 (14.9)  | 22 (14.5)  | 23 (12.1)  | 43 (10.3)  | Reference          | Reference       | Reference            |
| Genotype frequency |       |     |           |         |                   |                |                     |
| TT           | 71 (70.3)  | 56 (73.7)  | 75 (78.9)  | 167 (80.3) | Reference          | Reference       | Reference            |
| TC           | 30 (29.7)  | 18 (23.7)  | 17 (17.9)  | 39 (18.7)  | 0.035              | 1.009           | 1.031               |
| CC           | 0 (0.0)    | 2 (2.6)    | 3 (3.2)    | 2 (1.0)    | 2.573              | 0.330           | 1.142               |
| HWE          | 0.080     | 0.705     | 0.121     | 0.868     | 0.001              | 0.001           | 0.001               |
| Recreational model |       |     |           |         |                   |                |                     |
| TT + TC      | 101 (100.0) | 74 (98.7) | 92 (96.8) | 206 (99.0) | Reference          | Reference       | Reference            |
| CC           | 0 (0.0)    | 2 (2.6)    | 3 (3.2)    | 2 (1.0)    | 0.573              | 0.330           | 0.330               |
| Dominant model |       |     |           |         |                   |                |                     |
| TT           | 71 (70.3)  | 56 (73.7)  | 75 (78.9)  | 167 (80.3) | Reference          | Reference       | Reference            |
| CC + TC      | 30 (29.7)  | 20 (26.3)  | 20 (21.1)  | 41 (19.7)  | 0.052              | 1.721           | 1.239               |
| rs907715     |         |     |           |         |                   |                |                     |
| Allele frequency |       |     |           |         |                   |                |                     |
| Allele G     | 115 (56.9) | 89 (58.6)  | 105 (55.3) | 234 (56.2) | Reference          | Reference       | Reference            |
| Allele A     | 87 (43.8)  | 63 (41.4)  | 85 (44.7)  | 182 (43.8) | 0.873              | 0.973           | 0.820               |
| Genotype frequency |       |     |           |         |                   |                |                     |
| GC           | 53 (30.7)  | 24 (37.0)  | 28 (27.5)  | 70 (31.3)  | Reference          | Reference       | Reference            |
| GA           | 49 (48.5)  | 41 (53.9)  | 49 (51.6)  | 45 (42.5)  | 0.715              | 1.106           | 1.352               |
| AA           | 19 (18.8)  | 11 (14.5)  | 18 (18.9)  | 44 (21.1)  | 0.000              | 0.916           | 0.729               |
| HWE          | 0.914     | 0.331     | 0.674     | 0.238     | Reference          | Reference       | Reference            |
| Recreational model |       |     |           |         |                   |                |                     |
| GC + GA      | 82 (81.2)  | 65 (85.5)  | 77 (81.1)  | 164 (78.8) | Reference          | Reference       | Reference            |
| AA           | 19 (18.8)  | 11 (14.5)  | 18 (18.9)  | 44 (21.2)  | 0.632              | 0.864           | 0.659               |
| Dominant model |       |     |           |         |                   |                |                     |
| GC           | 33 (32.7)  | 24 (31.6)  | 29 (29.0)  | 70 (33.7)  | Reference          | Reference       | Reference            |
| AA + GA      | 68 (67.3)  | 52 (68.4)  | 67 (70.5)  | 138 (66.3) | 0.864              | 1.045           | 1.099               |
| Fisher’s exact test; \( \chi^2 \) test cannot be conducted due to cross tabulation of zero. CHB: Chronic hepatitis B; HWE: Hardy-Weinberg equilibrium.

rs907715 and chronic HBV infection, which is consistent with Li et al.\(^{24}\). The association between this SNP and immune disease has been widely investigated, though the findings are controversial. In a Chinese population, rs907715 was associated with Graves’ disease\(^{31}\) rather than SLE\(^{25}\), and the two studies had a similar sample size. This discrepancy may be attributable to different diseases. Two studies investigated the same disease in an African-American population. Hughes et al.\(^{31}\) found that G allele increased the risk of SLE, but Sawalha et al.\(^{29}\) drew the opposite conclusion. These findings require further replication in other independent cohorts of chronic HBV-infected patients.

The data regarding ATA haplotype frequency (rs13143866, rs2221903, and rs907715) in HCC patients compared to non-HCC patients showed that this haplotype may be a risk for HBV-related HCC. This result suggests that the haplotype, according to the IL21 polymorphisms, might be one of the most important genetic factors for susceptibility to HBV-related HCC.
In conclusion, our study demonstrates that genotypes rs13143866 AA and rs2221903 TC are risk factors for carrying HBV, and ATA haplotype increase the risk of HBV-related HCC onset in a Chinese population. However, further studies are needed to determine the associations and functional consequences of these polymorphisms in chronic HBV-infection susceptibility.

### COMMENTS

#### Background

The pathogenesis of chronic hepatitis B virus (HBV) infection is complicated, and the adaptive immune response plays a significant role in the pathophysiology of the process. Interleukin (IL)-21 is a relatively recently discovered multifunctional and pleiotropic cytokine. Recently, investigations have shown that the serum level of IL-21 was increased in chronic hepatitis B patients and associated with severe liver inflammation. Genetic polymorphisms in IL21 have been explored concerning genetic susceptibility to autoimmune and chronic HBV-infected diseases.

#### Research frontiers

The relationship between single-nucleotide polymorphisms (rs13143866, rs2221903, and rs907715) and autoimmune disease varies in different ethnicities. Therefore, studies performed using the same procedures and methods and enrolling more ethnic groups are required. In addition, further studies are needed to determine the associations and functional consequences of these polymorphisms in chronic HBV-infection susceptibility.

#### Innovations and breakthroughs

This is the first published study to investigate the relationship between the IL21 rs13143866 polymorphism and chronic HBV-infection susceptibility.

#### Applications

Physicians should pay more attention to individuals who have the rs13143866 AA or rs2221903 TC genotype, or ATA haplotype (rs13143866, rs2221903, and rs907715), and provide early intervention before chronic HBV infection develops and leads to hepatocellular carcinoma.

#### Terminology

Single-nucleotide polymorphisms refer to DNA sequence polymorphisms at the genomic level caused by a single nucleotide mutation. HBV is a DNA virus, which belongs to the hepatotropic DNA virus (Hepadnaviridae) group, and causes hepatitis B disease.

### Peer-review

In this study, authors investigated the relationship between single-nucleotide polymorphisms in IL21 and chronic HBV infection in a Chinese population. They found that the rs13143866 A allele increases the risk of HBV infection and ATA haplotype (rs13143866, rs2221903, and rs907715) increases the risk of HBV-related hepatocellular carcinoma.

### Table 5: Haplotype analysis of polymorphisms

| Haplotype | Frequency | χ² | P value | OR | 95%CI |
|-----------|-----------|----|---------|----|------|
| HBV infection | Control |       |         |    |      |
| A-T-A     | 0.150     | 0.127| 1.117   | 0.291| 1.209| 0.850-1.720 |
| G-C-G     | 0.137     | 0.103| 2.725   | 0.099| 1.376| 0.941-2.011 |
| G-T-A     | 0.283     | 0.31 | 0.883   | 0.347| 0.882| 0.678-1.147 |
| G-T-G     | 0.429     | 0.459| 0.959   | 0.327| 0.886| 0.695-1.129 |
| HCC       | non-HCC   |       |         |    |      |
| A-T-A     | 0.165     | 0.104| 4.057   | 0.044| 1.700| 1.010-2.863 |
| A-T-G     | 0.138     | 0.133| 0.917   | 0.900| 1.033| 0.635-1.681 |
| G-T-A     | 0.267     | 0.333| 3.226   | 0.072| 0.072| 0.503-1.031 |
| G-T-G     | 0.430     | 0.423| 0.009   | 0.926| 1.016| 0.726-1.422 |

1Haplotype of rs13143866 (G/A), rs2221903 (T/C), and rs907715 (G/A). HBV: Hepatitis B virus; HCC: Chronic HBV-infected patients with hepatocellular carcinoma; non-HCC: Chronic HBV-infected patients without hepatocellular carcinoma.

#### REFERENCES

1 European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436645 DOI: 10.1016/j.jhep.2012.02.010]

2 Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27: 6550-6557 [PMID: 19729084 DOI: 10.1016/j.vaccine.2009.08.048]

3 Chinese Society Of Hepatology And Chinese Society Of Infectious Diseases, Chinese Medical Association. [The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. Zhonghua Liu Xing Bing Xue Zaxi 2011; 32: 405-415 [PMID: 21569677]

4 Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M, Brandt C, Kuijper JL, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F, Bort S, Hamby K, Madri S, Clegg C, Moore M, Grant FJ, Lofton-Day C, Gilbert T, Rayford F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Mauer K, Kauanskys K, Holly RD, Foster D. Interleukin 21 and its receptor are involved in chronic HBV cell expansion and regulation of lymphocyte function. Nature 2000; 408: 57-63 [PMID: 11081504 DOI: 10.1038/35040504]

5 Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008; 26: 57-79 [PMID: 17953510 DOI: 10.1146/annurev.immunol.26.021607.093016]

6 Leonard WJ, Zeng R, Spolski R. Interleukin 21: a cytokine/cytokine receptor system that has come of age. J Leukoc Biol 2008; 84: 348-356 [PMID: 18467657 DOI: 10.1189/jlb.0308149]

7 Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, Spolski R, Leonard WJ, Lipsky PE. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005; 175: 7867-7879 [PMID: 16339522]

8 Ettinger R, Sims GP, Robbins R, Withers D, Fischer RT, Grammer AC, Kuchen S, Lipsky PE. IL-21 and BAFF/Ly5 synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol 2007; 178: 2872-2882 [PMID: 17312131]

9 Yang L, Anderson DE, Baechler-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008; 454: 350-352 [PMID: 18469800 DOI: 10.1038/nature07021]

10 Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, Oukka M, Kuchroo VK. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448: 484-487 [PMID: 17581588 DOI: 10.1038/nature05970]

11 Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. Biofactors 2010; 36: 274-288 [PMID: 20623510 DOI: 10.1002/biof.107]

12 Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science 2009; 324: 1569-1572 [PMID: 19423777 DOI: 10.1126/science.1174182]

13 Fröhlich A, Kisielow J, Schmitz I, Freigang S, Shanmugheat AV, Weber J, Marsland BJ, Oxenius A, Kopf M. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 2009; 324: 1576-1580 [PMID: 19478140 DOI: 10.1126/science.1172815]

14 Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009; 324: 1572-1576 [PMID: 19443735 DOI: 10.1126/science.1175194]

15 Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne S, Williams R, Rusheiko G, Bertolotti A. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78: 5707-5719 [PMID: 15140968]
Yao JY et al. IL-21 polymorphisms in China

DOI: 10.1128/JVI.78.11.5707-5719.2004

16 Chang JJ, Wightman F, Bartholomeusz A, Ayres A, Kent SJ, Sassadeusz J, Lewin SR. Reduced interleukin-21 receptor expression in human immunodeficiency virus type 1-HBV-infected individuals receiving HBV-active antiretroviral therapy. J Virol 2005; 79: 3038-3051 [PMID: 15709024 DOI: 10.1128/JVI.79.5.3038-3051.2005]

17 Boni C, Fiscarpo P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerba A, Cavalli A, Missale G, Bertolotti A, Ferrari C. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007; 81: 4215-4225 [PMID: 17287266 DOI: 10.1128/JVI.02844-06]

18 Urbani S, Boni C, Amadei B, Fiscarpo P, Cerioni S, Valli MA, Missale G, Ferrari C. Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology 2005; 41: 826-831 [PMID: 15726541 DOI: 10.1002/hep.20614]

19 Hu X, Ma S, Huang X, Jiang X, Zhu X, Gao H, Xu M, Sun J, Abbott WG, Hou J. Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease. J Viral Hepat 2013; 20: 458-467 [PMID: 21692955 DOI: 10.1111/j.1365-2893.2011.01475.x]

20 Pan Q, Yu Y, Tang Z, Xi M, Jiang H, Xun Y, Liu X, Liu H, Hu J, Zhang G. Increased levels of IL-21 responses are associated with the severity of liver injury in patients with chronic active hepatitis B. J Viral Hepat 2014; 21: e78-e88 [PMID: 24611989 DOI: 10.1111/jvhe.12242]

21 Hughes T, Kim-Howard X, Kelly JA, Kaufman KM, Langelfend CD, Ziegler J, Sanchez E, Kimberly RP, Edberg JC, Ramsey-Goldman R, Petri M, Revellie JD, Martin J, Brown EE, Vitá LM, Alarcón GS, James JA, Gilkeson GS, Moser KL, Gaffney PM, Merrill JT, Vyse TJ, Alarcón-Riquelme ME, Nath SK, Harley JB, Sawalha AH. Fine-mapping and transethnic genotyping establish IL21R gene polymorphisms with HBV infection in kidney transplant patients. Viral Immunol 2013; 26: 201-206 [PMID: 23656167 DOI: 10.1089/vim.2013.0007]

24 Li N, Zhu Q, Li Z, Han Q, Chen J, Lv Y, Wang Y, Zeng X, Chen Y, Yang C, Liu Z. IL21 and IL21R polymorphisms and their interactive effects on serum IL-21 and IgE levels in patients with chronic hepatitis B virus infection. Hum Immunol 2013; 74: 567-573 [PMID: 23354321 DOI: 10.1016/j.humimm.2013.01.005]

25 Ding L, Wang S, Chen GM, Leng RX, Pan HF, Ye DQ. A single nucleotide polymorphism of IL-21 gene is associated with systemic lupus erythematosus in a Chinese population. Inflammation 2012; 35: 1781-1785 [PMID: 22572563 DOI: 10.1002/art.3032010.1007/s10753-012-0497-7]

27 Messaoudi S, Al-Khateeb GM, Dendana M, Sater MS, Jazia KB, Nouriya M, Almawi YW, Mahjoub T. Genetic variations in the interleukin-21 gene and the risk of recurrent idiopathic spontaneous miscarriage. Eur Cytokine Netw 2011; 22: 123-126 [PMID: 21768062 DOI: 10.1684/ecn.2011.0287]

28 Thompson SD, Sudman M, Ramos PS, Marion MC, Ryan M, Tsoras M, Weiler T, Wagner M, Keddache M, Haas JP, Mueller C, Prahalad S, Bohnsack J, Wise CA, Panaro M, Zhang D, Rosé CD, Comeau ME, Divers J, Glass DN, Langefeld CF. The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1. Arthritis Rheum 2010; 62: 3265-3276 [PMID: 20722033 DOI: 10.1002/art.27688]

29 Sawalha AH, Kaufman KM, Kelly JA, Adler AJ, Aberle T, Kilpatrick J, Wakeland EK, Li QZ, Wandstrat AE, Karp DR, Sundan M, Ramos PS, Marion MC, Ryan M, Tsoras M, Weiler T, Wagner M, Keddache M, Haas JP, Mueller C, Prahalad S, Bohnsack J, Wise CA, Panaro M, Zhang D, Rosé CD, Comeau ME, Divers J, Glass DN, Langefeld CF. The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1. Arthritis Rheum 2010; 62: 3265-3276 [PMID: 20722033 DOI: 10.1002/art.27688]

30 Ma SW, Huang X, Li Y, Tang LB, Sun XF, Zhang XT, Zhang YX, Liu J, Zou SW, Zou HW, Hou J. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBcAg seroconversion in chronic hepatitis B. J Hepatol 2012; 56: 775-781 [PMID: 22173154 DOI: 10.1016/j.jhep.2011.10.020]

31 Jia HY, Zhang ZG, Gu XJ, Guo T, Cui B, Ning G, Zhao YJ. Association between interleukin-21 and Graves' disease. Genet Mol Res 2011; 10: 3338-3346 [PMID: 22057994 DOI: 10.4238/2011.10.31.6]
